ASH 2022 | The combination of copanlisib and nivolumab in patient’s with Richter’s transformation
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, talks on the results of a study evaluating the efficacy of copanlisib and nivolumab in patients with Richter’s transformation (NCT03884998), explaining that this combination appeared to be efficacious, especially in patients who developed immune-mediated toxicity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Nurix: Consultancy, Research Funding; Takeda Oncology: Research Funding; Astra Zeneca: Consultancy, Research Funding; Bayer Oncology: Research Funding; Bristol-Meyers-Squibb: Consultancy, Research Funding; Cyclacel: Research Funding; MEI: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding; Genentech: Consultancy; Morphosys: Consultancy; Incyte: Consultancy; Beigene: Consultancy; GSK: Consultancy; Pharmacyclics: Consultancy.
